KRAS and non-small cell lung carcinoma: Eklund E.A. et al. [28], in their study with 580 participating patients with NSCLC, showed that KRAS mutation is a negative prognostic factor for OS irrelevant of treatment options, with a significant negative factor when treated with platinum doublet ((p = 0.001) with median OS 9 months vs. KRASWT 14 months).